Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
July 2016
-
Press release
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product … -
Press release
New data shows Sandoz biosimilar etanercept candidate has equivalent efficacy to originator product
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the… -
In The News
Novartis Access perspectives: Kenya's New Health Care Battle
An opinion piece by Dr. Samuel Mwenda published in US News & World Report -
Featured News
Novartis: evolving business practices to better educate the medical community
Seeking to evolve the way it educates and engages with healthcare professionals, Novartis is using digital technology to enhance the quality, transparency and reach of its interactions with the medical community.
June 2016
-
In The News
Perfecting access through embedded sustainability, pooling resources and consolidating expertise
A guest blog post from Anthony Gitau, Country Head of Novartis Access and Familia Nawiri in Kenya. -
Press release
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[… -
Story From Our Labs
Molecular glue kills cancer cells in mice
Compounds block a protein involved in many cancers by cementing it shut.
-
Press release
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
Global survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1] Nearly half (45%) have been asked if they are contagious while 55% do not… -
Press release
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's… -
Story From Our Labs
Tuning drugs to succeed on the cell’s surface
Researchers improve our understanding about how compounds bind to proteins in the cell membrane—and the membrane itself.
-
Press release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts… -
In The News
Expanding access to healthcare: What will it really take?
Head of global nonprofit PATH explores how “social innovation” such as the Novartis Access program is helping expand access to healthcare in some of the world’s poorest countries.